NO930440L - Tri- og tetravalente monospesifikke antigen-bindingsproteiner - Google Patents
Tri- og tetravalente monospesifikke antigen-bindingsproteinerInfo
- Publication number
- NO930440L NO930440L NO93930440A NO930440A NO930440L NO 930440 L NO930440 L NO 930440L NO 93930440 A NO93930440 A NO 93930440A NO 930440 A NO930440 A NO 930440A NO 930440 L NO930440 L NO 930440L
- Authority
- NO
- Norway
- Prior art keywords
- tri
- antigen binding
- binding proteins
- monospecific antigen
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919112536A GB9112536D0 (en) | 1991-06-11 | 1991-06-11 | Chemical compounds |
PCT/GB1992/001047 WO1992022583A2 (en) | 1991-06-11 | 1992-06-11 | Tri- and tetra-valent monospecific antigen-binding proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
NO930440D0 NO930440D0 (no) | 1993-02-09 |
NO930440L true NO930440L (no) | 1993-04-02 |
Family
ID=10696461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO93930440A NO930440L (no) | 1991-06-11 | 1993-02-09 | Tri- og tetravalente monospesifikke antigen-bindingsproteiner |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0560947B1 (no) |
JP (1) | JP3373849B2 (no) |
KR (1) | KR930701490A (no) |
AT (1) | ATE192457T1 (no) |
AU (1) | AU1971692A (no) |
CA (1) | CA2088367C (no) |
DE (1) | DE69230994T2 (no) |
DK (1) | DK0560947T3 (no) |
ES (1) | ES2146212T3 (no) |
FI (1) | FI930580A (no) |
GB (1) | GB9112536D0 (no) |
NO (1) | NO930440L (no) |
NZ (1) | NZ243099A (no) |
WO (1) | WO1992022583A2 (no) |
ZA (1) | ZA924271B (no) |
Families Citing this family (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69331735T2 (de) * | 1992-12-10 | 2002-09-26 | Celltech Therapeutics Ltd., Slough | Gegen das A33 Antigen gerichtete Humanisierte Antikörper |
DE4310142A1 (de) * | 1993-03-29 | 1994-10-06 | Boehringer Mannheim Gmbh | Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung |
DE4310141A1 (de) * | 1993-03-29 | 1994-10-06 | Boehringer Mannheim Gmbh | Homobidentale trifunktionelle Linker |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
AU4761601A (en) | 2000-04-11 | 2001-10-23 | Genentech Inc | Multivalent antibodies and uses therefor |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
ATE518885T1 (de) | 2002-05-28 | 2011-08-15 | Ucb Pharma Sa | Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870) |
NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) * | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
WO2007031734A1 (en) | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A. | Comb polymers |
EP2336181A1 (en) | 2005-12-09 | 2011-06-22 | UCB Pharma, S.A. | Antibody molecules having specificity for human IL-6 |
EP2275816A3 (en) | 2006-03-22 | 2011-06-29 | Viral Logic Systems Technology Corp. | Methods for identifying polypeptide targets and uses thereof for treating immunological diseases |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
JP4780405B2 (ja) * | 2006-08-29 | 2011-09-28 | アイシン精機株式会社 | 結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法 |
EP1897886A1 (en) * | 2006-09-08 | 2008-03-12 | Bayer Schering Pharma Aktiengesellschaft | Compounds as aptamer-dimers and their uses in diagnosis and therapy |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
KR101761929B1 (ko) | 2009-02-17 | 2017-07-26 | 유씨비 바이오파마 에스피알엘 | 인간 ox40에 대한 특이성을 갖는 항체 분자 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
US20120283415A1 (en) | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
JP6095368B2 (ja) | 2009-10-27 | 2017-03-15 | ユセベ ファルマ ソシエテ アノニム | 機能改変するNav1.7抗体 |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
US10472426B2 (en) | 2010-03-25 | 2019-11-12 | Ucb Biopharma Sprl | Disulfide stabilized DVD-Ig molecules |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
EP2380909A1 (en) | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
CN101962503B (zh) * | 2010-08-27 | 2013-01-02 | 东华大学 | 耐高温电磁线自粘漆及其制备方法 |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
EA037071B1 (ru) | 2011-01-14 | 2021-02-02 | Юсб Байофарма Срл | Молекулы антител, которые связываются с il-17a и il-17f |
PT2731973T (pt) | 2011-07-13 | 2018-02-22 | Ucb Biopharma Sprl | Estirpe hospedeira bacteriana que expressa dsbc recombinante |
EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
EA032475B1 (ru) | 2011-09-16 | 2019-06-28 | Юсб Фарма С.А. | Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
PT2776466T (pt) | 2011-11-11 | 2017-11-30 | Ucb Biopharma Sprl | Anticorpos de ligação a albumina e seus fragmentos de ligação |
EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
EP2786766A1 (en) * | 2013-04-05 | 2014-10-08 | Ufpeptides S.r.l. | Supramolecular aggregates comprising maleimido cores |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
CA2914189C (en) | 2013-06-21 | 2023-03-14 | Innate Pharma | Enzymatic conjugation of polypeptides |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3954703A3 (en) | 2014-05-29 | 2022-05-18 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
EA201790719A1 (ru) | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
CA2974807A1 (en) | 2015-01-26 | 2016-08-04 | Macrogenics, Inc. | Multivalent molecules comprising dr5-binding domains |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
EP3288584A2 (en) | 2015-04-30 | 2018-03-07 | President and Fellows of Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
AU2016269065B2 (en) | 2015-05-27 | 2022-06-02 | Ucb Biopharma Sprl | Method for the treatment of neurological disease |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
US10287343B2 (en) | 2015-07-06 | 2019-05-14 | Ucb Biopharma Sprl | Tau-binding antibodies |
AU2016289753C1 (en) | 2015-07-06 | 2021-08-05 | UCB Biopharma SRL | Tau-binding antibodies |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
DK3456346T3 (da) | 2015-07-30 | 2021-08-30 | Macrogenics Inc | Pd-1- og lag-3-bindingsmolekyler og fremgangsmåder til anvendelse deraf |
EP3359688B1 (en) | 2015-10-05 | 2021-06-16 | UCB Biopharma SRL | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
MX2018004177A (es) | 2015-10-08 | 2018-09-11 | Macrogenics Inc | Terapia de combinacion para el tratamiento de cancer. |
SG11201802887PA (en) | 2015-10-27 | 2018-05-30 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
MX2018007089A (es) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ror1-結合分子及其使用方法 |
CR20180484A (es) | 2016-04-15 | 2019-03-05 | Macrogenics Inc | Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos |
WO2017213695A1 (en) | 2016-06-07 | 2017-12-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
JP2020500834A (ja) | 2016-08-26 | 2020-01-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | マクロファージ刺激タンパク質受容体(又はRON(Recepteur d′Origine Nantais))抗体及びその使用 |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
KR102630036B1 (ko) | 2016-12-23 | 2024-01-29 | 마크로제닉스, 인크. | Adam9-결합 분자, 및 이것의 사용 방법 |
BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
EP3619191A4 (en) * | 2017-05-05 | 2020-12-16 | Fusion Pharmaceuticals Inc. | PHARMACOKINETIC IMPROVEMENTS OF BIFUNCTIONAL CHELATES AND THEIR USES |
KR102651568B1 (ko) | 2017-05-19 | 2024-03-25 | 신닥스 파마슈티컬스, 인크. | 조합 요법 |
CN107652219B (zh) * | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
CN111465618A (zh) | 2017-12-12 | 2020-07-28 | 宏观基因有限公司 | 双特异性cd16-结合分子及其在疾病治疗中的用途 |
GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
JP7337079B2 (ja) | 2018-02-15 | 2023-09-01 | マクロジェニクス,インコーポレーテッド | 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
BR112021002164A2 (pt) | 2018-08-13 | 2021-08-03 | Inhibrx, Inc. | polipeptídeos de ligação a ox40 e usos dos mesmos |
SG11202103801UA (en) | 2018-10-16 | 2021-05-28 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
EP3947457A1 (en) | 2019-03-26 | 2022-02-09 | ASLAN Pharmaceuticals Pte Ltd | Treatment employing anti-il-13r antibody or binding fragment thereof |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
US20230089620A1 (en) | 2020-02-21 | 2023-03-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-IL-2 Antibody, and Antigen-Binding Fragment Thereof and Medical Use Thereof |
CA3182362A1 (en) | 2020-05-14 | 2021-11-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
CN117487016A (zh) | 2020-07-02 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 抗FXI/FXIa抗体、其抗原结合片段及医药用途 |
EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
JP2023535598A (ja) | 2020-07-27 | 2023-08-18 | 上海拓界生物医薬科技有限公司 | 抗cd79b抗体薬物複合体、その調製方法及びその医薬用途 |
MX2023004436A (es) | 2020-10-15 | 2023-05-08 | UCB Biopharma SRL | Moleculas de union que multimerizan cd45. |
JP2023550596A (ja) | 2020-11-02 | 2023-12-04 | ユーシービー バイオファルマ エスアールエル | 運動ニューロン神経変性障害の治療のための抗trem1中和抗体の使用 |
CA3202233A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic BioPharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
AU2021398385A1 (en) | 2020-12-07 | 2023-07-13 | UCB Biopharma SRL | Antibodies against interleukin-22 |
CN116670166A (zh) | 2020-12-07 | 2023-08-29 | Ucb生物制药有限责任公司 | 多特异性抗体和抗体组合 |
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
US20240209114A1 (en) | 2021-04-25 | 2024-06-27 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof |
US20240254224A1 (en) | 2021-05-03 | 2024-08-01 | UCB Biopharma SRL | Antibodies |
CN117295764A (zh) | 2021-06-28 | 2023-12-26 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及医药用途 |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
EP4393949A1 (en) | 2021-08-25 | 2024-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing fusion protein |
WO2023040945A1 (zh) | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | 特异性结合pd-1的蛋白及其医药用途 |
WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
WO2023075702A1 (en) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
TW202342535A (zh) | 2022-02-11 | 2023-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 免疫綴合物及其用途 |
WO2023163659A1 (en) | 2022-02-23 | 2023-08-31 | Aslan Pharmaceuticals Pte Ltd | Glycosylated form of anti-il13r antibody |
GB202210679D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-12rb2 |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024054157A1 (en) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
WO2024115393A1 (en) | 2022-11-28 | 2024-06-06 | UCB Biopharma SRL | Treatment of fibromyalgia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU593611B2 (en) * | 1986-02-14 | 1990-02-15 | Nihon Medi-Physics Co., Ltd. | High molecular compounds having amino groups, and their utilization |
EP0271180B2 (en) * | 1986-08-18 | 1997-06-18 | The Dow Chemical Company | Starburst conjugates |
GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8903022D0 (en) * | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
AU6290090A (en) * | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
CA2045150A1 (en) * | 1989-11-07 | 1991-05-08 | Walt W. Shuford | Oligomeric immunoglobulins |
US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
GB9012995D0 (en) * | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
-
1991
- 1991-06-11 GB GB919112536A patent/GB9112536D0/en active Pending
-
1992
- 1992-06-11 DE DE69230994T patent/DE69230994T2/de not_active Expired - Lifetime
- 1992-06-11 CA CA002088367A patent/CA2088367C/en not_active Expired - Lifetime
- 1992-06-11 AT AT92912329T patent/ATE192457T1/de not_active IP Right Cessation
- 1992-06-11 NZ NZ243099A patent/NZ243099A/en not_active IP Right Cessation
- 1992-06-11 EP EP92912329A patent/EP0560947B1/en not_active Expired - Lifetime
- 1992-06-11 ZA ZA924271A patent/ZA924271B/xx unknown
- 1992-06-11 DK DK92912329T patent/DK0560947T3/da active
- 1992-06-11 WO PCT/GB1992/001047 patent/WO1992022583A2/en active IP Right Grant
- 1992-06-11 AU AU19716/92A patent/AU1971692A/en not_active Abandoned
- 1992-06-11 JP JP51108392A patent/JP3373849B2/ja not_active Expired - Fee Related
- 1992-06-11 KR KR1019930700387A patent/KR930701490A/ko not_active Application Discontinuation
- 1992-06-11 ES ES92912329T patent/ES2146212T3/es not_active Expired - Lifetime
-
1993
- 1993-02-09 NO NO93930440A patent/NO930440L/no unknown
- 1993-02-10 FI FI930580A patent/FI930580A/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0560947A1 (en) | 1993-09-22 |
NO930440D0 (no) | 1993-02-09 |
EP0560947B1 (en) | 2000-05-03 |
DE69230994T2 (de) | 2001-02-01 |
FI930580A0 (fi) | 1993-02-10 |
KR930701490A (ko) | 1993-06-11 |
CA2088367A1 (en) | 1992-12-12 |
AU1971692A (en) | 1993-01-12 |
DK0560947T3 (da) | 2000-08-07 |
DE69230994D1 (de) | 2000-06-08 |
WO1992022583A3 (en) | 1993-04-01 |
GB9112536D0 (en) | 1991-07-31 |
ES2146212T3 (es) | 2000-08-01 |
CA2088367C (en) | 2002-08-20 |
WO1992022583A2 (en) | 1992-12-23 |
NZ243099A (en) | 1996-07-26 |
ATE192457T1 (de) | 2000-05-15 |
FI930580A (fi) | 1993-04-02 |
JPH06502657A (ja) | 1994-03-24 |
JP3373849B2 (ja) | 2003-02-04 |
ZA924271B (en) | 1993-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO930440L (no) | Tri- og tetravalente monospesifikke antigen-bindingsproteiner | |
CA2124953A1 (en) | Peptides related to prion proteins | |
HUP9802401A2 (hu) | Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására | |
DK113389D0 (da) | Monoklonale antistoffer | |
FI970198A0 (fi) | Ihmisen immuunikatoviruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet | |
GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
WO1996021734A3 (en) | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
SE8601644D0 (sv) | Antikroppspreparation riktad mot vissa determinanter i human c3 samt dess anvendning och framstellning | |
FI900230A0 (fi) | Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma. | |
DK0749481T3 (da) | Humaniserede monoklonale antistoffer mod human interleukin-4 | |
DE69637130D1 (de) | Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren | |
DE3884646D1 (de) | Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper. | |
DE3585370D1 (de) | Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen. | |
NO950526D0 (no) | T-celleepitoper av raigresspollen-allergen | |
DE3687542D1 (de) | Monoklonaler antikoerper gegen humanes protein c. | |
GR890100333A (en) | Antihuman antigen antibodies | |
GB2333295A (en) | Modified protein G and fragments thereof | |
NO914094D0 (no) | Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer | |
ATE48638T1 (de) | Monoklonaler antikoerper gegen ein humanes tumor- karzinom-assoziiertes antigen. |